| Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D S Liu, W Tang, J Zhou, JR Stubbs, Q Luo, M Pi, LD Quarles Journal of the American Society of Nephrology 17 (5), 1305-1315, 2006 | 864 | 2006 |
| Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden JR Stubbs, JA House, AJ Ocque, S Zhang, C Johnson, C Kimber, ... Journal of the American Society of Nephrology 27 (1), 305-313, 2016 | 454 | 2016 |
| Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice JR Stubbs, S Liu, W Tang, J Zhou, Y Wang, X Yao, LD Quarles Journal of the American Society of Nephrology 18 (7), 2116-2124, 2007 | 354 | 2007 |
| Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD JR Stubbs, A Idiculla, J Slusser, R Menard, LD Quarles Journal of the American Society of Nephrology 21 (2), 353-361, 2010 | 262 | 2010 |
| FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy CD Touchberry, TM Green, V Tchikrizov, JE Mannix, TF Mao, BW Carney, ... American Journal of Physiology-Endocrinology and Metabolism 304 (8), E863-E873, 2013 | 220 | 2013 |
| FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability N Silswal, CD Touchberry, DR Daniel, DL McCarthy, S Zhang, J Andresen, ... American Journal of Physiology-Endocrinology and Metabolism 307 (5), E426-E436, 2014 | 208 | 2014 |
| Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. J Stubbs, S Liu, LD Quarles Seminars in dialysis 20 (4), 2007 | 179 | 2007 |
| Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets US Alon, R Levy-Olomucki, WV Moore, J Stubbs, S Liu, LD Quarles Clinical Journal of the American Society of Nephrology 3 (3), 658-664, 2008 | 164 | 2008 |
| Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease JR Stubbs, N He, A Idiculla, R Gillihan, S Liu, V David, Y Hong, ... Journal of Bone and Mineral Research 27 (1), 38-46, 2012 | 130 | 2012 |
| Development and validation of a simple UHPLC–MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human … AJ Ocque, JR Stubbs, TD Nolin Journal of pharmaceutical and biomedical analysis 109, 128-135, 2015 | 73 | 2015 |
| Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis JR Stubbs, MR Stedman, S Liu, J Long, Y Franchetti, RE West III, ... Clinical Journal of the American Society of Nephrology 14 (2), 261-267, 2019 | 70 | 2019 |
| Microbiome and cardiovascular disease in CKD A Jovanovich, T Isakova, J Stubbs Clinical Journal of the American Society of Nephrology 13 (10), 1598-1604, 2018 | 67 | 2018 |
| Decreased conversion of 25-hydroxyvitamin D3 to 24, 25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD JR Stubbs, S Zhang, PA Friedman, TD Nolin Clinical Journal of the American Society of Nephrology 9 (11), 1965-1973, 2014 | 62 | 2014 |
| Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD A Jovanovich, T Isakova, G Block, J Stubbs, G Smits, M Chonchol, ... American Journal of Kidney Diseases 71 (1), 27-34, 2018 | 60 | 2018 |
| Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease S Zhang, R Gillihan, N He, T Fields, S Liu, T Green, JR Stubbs Kidney international 84 (4), 713-721, 2013 | 42 | 2013 |
| Decreased kidney function is associated with enhanced hepatic flavin monooxygenase activity and increased circulating trimethylamine N-oxide concentrations in mice C Johnson, AJ Prokopienko, RE West, TD Nolin, JR Stubbs Drug Metabolism and Disposition 46 (9), 1304-1309, 2018 | 40 | 2018 |
| Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25 (OH) D) repletion in chronic kidney disease: a randomised clinical trial JB Wetmore, C Kimber, JD Mahnken, JR Stubbs British Journal of Nutrition 116 (12), 2074-2081, 2016 | 37 | 2016 |
| Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: an application in patients with kidney disease AJ Prokopienko, RE West III, JR Stubbs, TD Nolin Journal of pharmaceutical and biomedical analysis 174, 618-624, 2019 | 34 | 2019 |
| Trimethylamine-N-oxide acutely increases cardiac muscle contractility CI Oakley, JA Vallejo, D Wang, MA Gray, LAM Tiede-Lewis, T Shawgo, ... American Journal of Physiology-Heart and Circulatory Physiology 318 (5 …, 2020 | 30 | 2020 |
| Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? JR Stubbs, JB Wetmore Seminars in Dialysis 24 (3), 298-306, 2011 | 25 | 2011 |
